Form 4: Monopar Therapeutics: Insider Stock Transactions
Insider Transaction Report
Chandler Robinson, CEO and Director of Monopar Therapeutics, reported transactions involving restricted stock units and common stock.
Summary
- Chandler Robinson, Chief Executive Officer and Director of Monopar Therapeutics, reported transactions on June 30, 2026.
- These transactions involved the acquisition of 12,873 shares of common stock upon the vesting and settlement of restricted stock units (RSUs).
- Additionally, 4,084 shares were withheld by the issuer to cover applicable taxes due upon the vesting of RSUs.
- Following these transactions, Robinson beneficially owns 103,351 shares directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust.
- The filing details several RSU grants with staggered vesting schedules extending through December 2029.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to executive compensation and vesting schedules, rather than a significant strategic event or performance indicator.
Positives
- Vesting of restricted stock units indicates continued incentive alignment for key management.
- The reporting person's direct and indirect beneficial ownership remains substantial, suggesting continued commitment to the company.
Negatives
- Withholding of shares to cover taxes represents a reduction in the net shares received by the reporting person.
Future Outlook
The filing details multiple grants of restricted stock units with vesting schedules extending through December 2029, indicating a long-term incentive structure for the reporting person.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and are closely watched by investors to gauge management's confidence in the company's prospects. The detailed RSU vesting schedules suggest a structured approach to executive compensation and retention within the biotechnology sector.
Stakeholder Impact
- Shareholders: The transactions reflect standard executive compensation practices and do not inherently signal a change in company strategy or performance. The continued ownership by management may be viewed positively.
- Employees: The RSU grants and vesting schedules are part of the overall compensation structure for key personnel.
- Management: The transactions represent the realization of equity-based compensation tied to performance and continued service.
Next Steps
- Continued vesting of restricted stock units according to the outlined schedules through December 2029.
Key Dates
| Date | Description |
|---|---|
| 05/20/2020 | Date of Irrevocable Trust U/A for Chandler D. Robinson. |
| 02/01/2023 | Grant date for a batch of 33,803 restricted stock units. |
| 03/04/2025 | Grant date for a batch of 79,899 restricted stock units. |
| 12/02/2025 | Grant date for a batch of 49,133 restricted stock units. |
| 06/30/2026 | Transaction date for vesting and settlement of RSUs, acquisition of common stock, and tax withholding. |
| 06/30/2026 | Vesting date for a portion of RSUs granted on December 2, 2025. |
| 12/31/2026 | Full vesting date for RSUs granted on February 1, 2023. |
| 12/31/2028 | Full vesting date for RSUs granted on March 4, 2025. |
| 12/31/2029 | Full vesting date for RSUs granted on December 2, 2025. |
Keywords
Monopar Therapeutics, MNPR, Form 4, Insider Trading, Restricted Stock Units, Common Stock, Beneficial Ownership, SEC Filing, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.